Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 73
1.
Infect Dis (Lond) ; 55(7): 467-479, 2023 07.
Article En | MEDLINE | ID: mdl-37151046

BACKGROUND: Mycobacterium haemophilum is a nontuberculous mycobacterium with fastidious in vitro growth requirements and an increasingly reported cause of extrapulmonary disease. Timely diagnosis and management of M. haemophilum infections and the immune reconstitution inflammatory syndromes (IRIS) observed in a subset of patients during treatment remain challenging. METHODS: We conducted a retrospective chart review between January 1, 2010, and January 1, 2022 and identified 26 patients diagnosed with M. haemophilum infection at our institution. We describe their clinical presentation, diagnostic results, management, and outcomes. RESULTS: The majority of patients in our cohort had upper and/or lower extremity skin involvement, were immunosuppressed, and had generally favourable treatment outcomes. All tested M. haemophilum isolates were susceptible in vitro to clarithromycin and trimethoprim-sulfamethoxazole. Moreover, high rates of susceptibility were noted for ciprofloxacin (95%), linezolid (90%), and rifampin (85%). IRIS was identified in 31% of cases and should be considered in patients who develop worsening skin lesions or systemic symptoms following the initiation of effective antimicrobial therapy. Visualisation of acid-fast bacilli on initial tissue stains, a positive mycobacterial blood culture, and rapid de-escalation of tumour necrosis factor-α inhibitors and/or corticosteroids were more frequently encountered among patients in our cohort who developed IRIS. CONCLUSION: M. haemophilum infection should be considered among patients receiving immunomodulatory therapy who develop discoloured or nodular skin lesions involving the extremities, worsening focal arthritis, tenosynovitis, or isolated adenopathy. A heightened awareness of this pathogen's clinical and laboratory characteristics can lead to a timely diagnosis and favourable outcome.


Immune Reconstitution Inflammatory Syndrome , Mycobacterium Infections , Mycobacterium haemophilum , Humans , Immune Reconstitution Inflammatory Syndrome/drug therapy , Immune Reconstitution Inflammatory Syndrome/microbiology , Mycobacterium Infections/drug therapy , Retrospective Studies , Treatment Outcome
2.
Front Immunol ; 12: 585316, 2021.
Article En | MEDLINE | ID: mdl-33868222

Central nervous system immune reconstitution inflammatory syndrome (CNS-IRIS) describes clinical characteristics that may be observed in previously immunocompromised patients during rapid restoration of immunity function in the presence of a pathogen. There have been no reports about CNS-IRIS related to bacterial meningitis so far. Here, we report a 24-year-old pregnant female patient with bacterial meningitis. Her clinical and neuroradiological condition worsened after induced labor despite great effective anti-infective therapy. CNS-IRIS was considered. Corticosteroids were administered, and the patient gradually recovered. We present the first case of CNS-IRIS associated with bacterial meningitis.


Central Nervous System Diseases/immunology , Central Nervous System/immunology , Immune Reconstitution Inflammatory Syndrome/immunology , Meningitis, Bacterial/immunology , Pregnancy Complications, Infectious/immunology , Adrenal Cortex Hormones/therapeutic use , Central Nervous System/drug effects , Central Nervous System/microbiology , Central Nervous System Diseases/drug therapy , Central Nervous System Diseases/microbiology , Female , Humans , Immune Reconstitution Inflammatory Syndrome/drug therapy , Immune Reconstitution Inflammatory Syndrome/microbiology , Meningitis, Bacterial/drug therapy , Meningitis, Bacterial/microbiology , Pregnancy , Pregnancy Complications, Infectious/drug therapy , Pregnancy Complications, Infectious/microbiology , Treatment Outcome , Young Adult
3.
J Infect Dis ; 223(7): 1275-1283, 2021 04 08.
Article En | MEDLINE | ID: mdl-32761193

BACKGROUND: Immune reconstitution inflammatory syndrome (IRIS) is a common cause of morbidity among people with human immunodeficiency virus (PWH) who initiate antiretroviral therapy (ART) with severe lymphopenia. Easily accessible tools that reliably predict emergence and elucidate pathogenesis of IRIS are needed to facilitate improved clinical management. METHODS: Plasma levels of biomarkers were measured before ART initiation in a large multinational cohort of ART-naive PWH with severe immunosuppression (CD4+ count <100 cells/mm3) in United States, Kenya, and Thailand. We performed a series of multiparametric analyses of inflammatory and clinical biomarkers and developed a composite score merging relevant biomarkers for use in a prediction model. RESULTS: We identified a distinct baseline inflammatory profile and changes in inflammatory networks among biomarkers in participants who subsequently developed mycobacterial or viral IRIS. We also developed a composite score incorporating biomarkers associated with IRIS (interleukin-6 [IL-6], IL-10, IL-27, sCD14, interferon-γ, tumor necrosis factor-α, hyaluronic acid, D-dimer, body mass index, and hemoglobin) that accurately predicted mycobacterial IRIS and death in this cohort. CONCLUSIONS: Systemic inflammatory profiles in PWH with severe immunosuppression are predictive of IRIS. Composite scores for the prediction of mycobacterial IRIS and death could be useful for risk stratification in PWH and lymphopenia initiating ART. CLINICAL TRIALS REGISTRATION: NCT00286767.


HIV Infections , Immune Reconstitution Inflammatory Syndrome , Lymphopenia , Biomarkers , HIV Infections/complications , HIV Infections/drug therapy , Humans , Immune Reconstitution Inflammatory Syndrome/microbiology , Prospective Studies
4.
Rev. iberoam. micol ; 37(3/4): 97-99, jul.-oct. 2020. ilus, tab
Article En | IBECS | ID: ibc-200360

BACKGROUND: Sporotrichosis has been occurring as outbreaks in Brazil, reaching epidemic levels in some regions. Zoonotic transmission is the main route to acquire Sporothrix. CASE REPORT: We describe a case of disseminated sporotrichosis caused by Sporothrix brasiliensis in an HIV/AIDS patient, with the presentation of immune reconstitution inflammatory syndrome (IRIS). CONCLUSIONS: This case reinforces that sporotrichosis should always be suspected in patients with IRIS from endemic regions, even in patients without the typical cutaneous lesions of this mycosis


ANTECEDENTES: La esporotricosis suele aparecer en Brasil en forma de brotes y alcanza tasas epidémicas en algunas regiones. La ruta principal de transmisión es la zoonótica. CASO CLÍNICO: Describimos un caso de esporotricosis diseminada causado por Sporothrix brasiliensis en una paciente con VIH/sida que presentó un síndrome inflamatorio de reconstitución inmune (SIRI). CONCLUSIONES: Este caso demuestra que en regiones endémicas de esporotricosis esta micosis siempre debe ser sospechada en casos de SIRI, incluso en pacientes sin las lesiones cutáneas típicas de esta enfermedad


Humans , Female , Adult , AIDS-Related Opportunistic Infections/diagnosis , AIDS-Related Opportunistic Infections/microbiology , Sporotrichosis/diagnosis , Sporotrichosis/microbiology , Sporothrix/isolation & purification , Immune Reconstitution Inflammatory Syndrome/diagnosis , Immune Reconstitution Inflammatory Syndrome/microbiology
6.
Cancer Immunol Immunother ; 69(12): 2665-2671, 2020 Dec.
Article En | MEDLINE | ID: mdl-32761425

INTRODUCTION: A hypersensitivity response akin to immune reconstitution inflammatory syndrome (IRIS) has been proposed as a mechanism responsible for anti-PD-1 therapy-induced tuberculosis. IRIS is associated with enhanced activation of IL-17A-expressing CD4 + T cells (Th17). Gut microbiota is thought to be linked to pulmonary inflammation through the gut-lung axis. MATERIALS AND METHODS: We used ImmuCellAI to investigate the T cell population in lung cancer and tuberculosis samples. Then, we applied flow cytometry to monitor the expression levels of the Th17 cell activation marker CD38 in the peripheral blood of a patient experiencing adverse events, including tuberculosis, in response to pembrolizumab. The gut microbiome was examined by 16S rRNA sequencing to examine the alterations caused by pembrolizumab. RESULTS: The percentage of Th17 cells was increased in both lung cancer and tuberculosis. FACS analysis showed that pembrolizumab induced substantial CD38 expression in Th17 cells. The patient's fecal samples showed that the diversity of the gut microbiota was significantly increased in response to the pembrolizumab cycle. One enriched genus was Prevotella, which has previously been linked to lung inflammation and Th17 immune activation. DISCUSSION: The observed Th17 activation in our patient was consistent with a role of Th17-mediated IRIS in pembrolizumab-triggered tuberculosis. Pembrolizumab might trigger airway inflammation with a Th17 phenotype through microbiota interactions in the gut-lung axis.


Antibodies, Monoclonal, Humanized/adverse effects , Gastrointestinal Microbiome/immunology , Immune Reconstitution Inflammatory Syndrome/immunology , Lung Neoplasms/drug therapy , Th17 Cells/immunology , Tuberculosis/immunology , Antitubercular Agents/therapeutic use , DNA, Bacterial/isolation & purification , Datasets as Topic , Gastrointestinal Microbiome/genetics , Humans , Immune Reconstitution Inflammatory Syndrome/blood , Immune Reconstitution Inflammatory Syndrome/chemically induced , Immune Reconstitution Inflammatory Syndrome/microbiology , Lung/diagnostic imaging , Lung/immunology , Lung/microbiology , Lung/pathology , Lung Neoplasms/blood , Lung Neoplasms/immunology , Lung Neoplasms/microbiology , Male , Middle Aged , Mycobacterium tuberculosis/immunology , Mycobacterium tuberculosis/isolation & purification , Prevotella/genetics , Prevotella/immunology , Prevotella/isolation & purification , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Programmed Cell Death 1 Receptor/immunology , RNA, Ribosomal, 16S/genetics , Th17 Cells/drug effects , Tomography, X-Ray Computed , Tuberculosis/chemically induced , Tuberculosis/drug therapy , Tuberculosis/microbiology
7.
BMC Infect Dis ; 20(1): 15, 2020 Jan 06.
Article En | MEDLINE | ID: mdl-31906936

BACKGROUND: Bacillus cereus sometimes causes central nervous system infection, especially in compromised hosts. In cases of meningitis arising during neutropenia, CSF abnormalities tend to be subtle and can be easily overlooked, and mortality rate is high. We report a survived case of B. cereus meningitis/brain abscess in severe neutropenia, presenting as immune reconstitution syndrome. CASE PRESENTATION: A 54-year-old Japanese female with acute myelogenous leukemia developed B. cereus bacteremia and meningitis during consolidation chemotherapy. At the onset, she presented with mild meningism. She had marked leukocytopenia (WBC <100/µL, neutrophils 0/µL) and lumbar puncture yielded only mild pleocytosis. She was transferred to intensive care unit, and meropenem, linezolid and vancomycin was started. With intensive therapy, she recovered and once became afebrile. On day 19, however, her fever, meningism and consciousness level dramatically worsened despite recovery of bone marrow function. The antimicrobial chemotherapy was continued and finally she was cured with no complications. CONCLUSIONS: With early diagnosis and prompt initiation and of antibiotics, the case was successfully treated without any sequelae. It is important to remember that, even under optimal antimicrobial therapy, bone marrow recovery can cause transient reaggravation of the disease. In such cases, timely and appropriate evaluation should be done to make the clinical decision to change, continue, or intensify treatment.


Bacteremia/complications , Brain Abscess/complications , Chemotherapy-Induced Febrile Neutropenia/complications , Immune Reconstitution Inflammatory Syndrome/complications , Meningitis, Bacterial/complications , Anti-Bacterial Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bacillus cereus/isolation & purification , Bacteremia/drug therapy , Bacteremia/microbiology , Brain Abscess/drug therapy , Brain Abscess/microbiology , Female , Humans , Immune Reconstitution Inflammatory Syndrome/drug therapy , Immune Reconstitution Inflammatory Syndrome/microbiology , Leukemia, Myeloid, Acute/drug therapy , Meningitis, Bacterial/drug therapy , Meningitis, Bacterial/microbiology , Middle Aged , Treatment Outcome
8.
Article En | MEDLINE | ID: mdl-31859848

Mycobacterium haemophilum is a nontuberculous mycobacterium that causes localized or disseminated disease, mainly in immunocompromised hosts. We report the case of a 35-year-old HIV-infected woman who presented with several enlarging cutaneous lesions over the arms and legs. Histopathological examination revealed the diagnosis of a cutaneous mycobacterial disease. Mycobacterial analyses unveiled M. haemophilum infection. Six months after completion of a successful antimycobacterial treatment, she developed an immune reconstitution inflammatory syndrome (IRIS). This paradoxical relapse presented as tenderness, redness and swelling at the precise sites of the healed lesions and took place in the setting of significant recovery of the CD4 cell count (from 05 to 318 cells/mm 3 ). Microbiological analyses of these worsening lesions were negative, and they spontaneously remitted without the initiation of a novel antimycobacterial treatment cycle. M. haemophilum infection should always be considered as a cause of skin lesions in immunocompromised subjects. Physicians should be aware of the possibility of IRIS as a complication of successful antiretroviral therapy in HIV-infected patients with M. haemophilum infection.


AIDS-Related Opportunistic Infections/microbiology , Anti-Retroviral Agents/adverse effects , Immune Reconstitution Inflammatory Syndrome/microbiology , Mycobacterium Infections/microbiology , Mycobacterium haemophilum/isolation & purification , AIDS-Related Opportunistic Infections/immunology , Adult , Anti-Retroviral Agents/therapeutic use , CD4 Lymphocyte Count , Female , Humans , Immune Reconstitution Inflammatory Syndrome/immunology , Immune Reconstitution Inflammatory Syndrome/metabolism , Immunocompromised Host , Male , Mycobacterium Infections/immunology
9.
J Infect Chemother ; 25(12): 1060-1064, 2019 Dec.
Article En | MEDLINE | ID: mdl-31227383

Mycobacterium genavense (M. genavense) is one of the most fastidious, difficult to culture Mycobacterium species. Patients infected with human immunodeficiency virus (HIV) may develop immune reconstitution inflammatory syndrome (IRIS) due to disseminated M. genavense infection as well as disseminated M. avium and intracellulare complex infection. Consensus regarding treatment of IRIS due to disseminated mycobacterium infection has not yet been obtained, although systemic steroid therapy has been recommended in recent guidelines. Here we report the case of a 48-year-old Japanese man diagnosed with HIV and disseminated M. genavense infection. His initial CD4-positive T cell count was 3/µL, and his HIV1-RNA viral load was 13,000 copies/mL. He developed IRIS due to disseminated M. genavense infection after two weeks of receiving antiretroviral agents. The patient's serum alkaline phosphatase level, as a barometer of disseminated M. genavense infection in this case, was difficult to control with several anti-mycobacterial agents, although his fever was improved by non-steroidal anti-inflammatory drugs. About five weeks after the onset of IRIS, the patient developed acute left upper quadrant pain and was diagnosed with splenic infarction by contrast-enhanced computed tomography. After the splenic infarction, the patient's serum alkaline phosphatase level decreased without systemic steroid therapy or anticoagulant agents, and his left upper quadrant pain improved naturally within a few days. This case suggests that IRIS due to disseminated M. genavense infection can complicate splenic infarction in patients with HIV, and splenic infarction could improve the IRIS due to disseminated M. genavense infection.


AIDS-Related Opportunistic Infections/complications , Immune Reconstitution Inflammatory Syndrome/microbiology , Mycobacterium Infections, Nontuberculous/complications , Mycobacterium/isolation & purification , Splenic Infarction/immunology , AIDS-Related Opportunistic Infections/drug therapy , AIDS-Related Opportunistic Infections/immunology , Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Humans , Immune Reconstitution Inflammatory Syndrome/complications , Immune Reconstitution Inflammatory Syndrome/drug therapy , Immune Reconstitution Inflammatory Syndrome/immunology , Male , Middle Aged , Mycobacterium/immunology , Mycobacterium Infections, Nontuberculous/drug therapy , Mycobacterium Infections, Nontuberculous/immunology , Mycobacterium Infections, Nontuberculous/microbiology , Spleen/blood supply , Spleen/diagnostic imaging , Splenic Infarction/diagnostic imaging , Tomography, X-Ray Computed , Treatment Outcome
10.
Front Immunol ; 10: 66, 2019.
Article En | MEDLINE | ID: mdl-30761136

Cryptococcus neoformans is a ubiquitous environmental yeast and a leading cause of invasive fungal infection in humans. The most recent estimate of global disease burden includes over 200,000 cases of cryptococcal meningitis each year. Cryptococcus neoformans expresses several virulence factors that may have originally evolved to protect against environmental threats, and human infection may be an unintended consequence of these acquired defenses. Traditionally, C. neoformans has been viewed as a purely opportunistic pathogen that targets severely immune compromised hosts; however, during the past decade the spectrum of susceptible individuals has grown considerably. In addition, the closely related strain Cryptococcus gattii has recently emerged in North America and preferentially targets individuals with intact immunity. In parallel to the changing epidemiology of cryptococcosis, an increasing role for host immunity in the pathogenesis of severe disease has been elucidated. Initially, the HIV/AIDS epidemic revealed the capacity of C. neoformans to cause host damage in the absence of adaptive immunity. Subsequently, the development and clinical implementation of highly active antiretroviral treatment (HAART) led to recognition of an immune reconstitution inflammatory syndrome (IRIS) in a subset of HIV+ individuals, demonstrating the pathological role of host immunity in disease. A post-infectious inflammatory syndrome (PIIRS) characterized by abnormal T cell-macrophage activation has also been documented in HIV-negative individuals following antifungal therapy. These novel clinical conditions illustrate the highly complex host-pathogen relationship that underlies severe cryptococcal disease and the intricate balance between tolerance and resistance that is necessary for effective resolution. In this article, we will review current knowledge of the interactions between cryptococci and mammalian hosts that result in a tolerant phenotype. Future investigations in this area have potential for translation into improved therapies for affected individuals.


Cryptococcus neoformans/immunology , Cryptococcus neoformans/pathogenicity , Disease Resistance/immunology , Immune Tolerance/immunology , Meningitis, Cryptococcal/microbiology , Adaptation, Physiological , Animals , CD4-Positive T-Lymphocytes/immunology , Cryptococcus gattii/immunology , Dendritic Cells/immunology , Host-Pathogen Interactions , Humans , Immune Reconstitution Inflammatory Syndrome/microbiology , Interleukin-10/metabolism , Mice , Virulence Factors/metabolism
11.
Infection ; 47(1): 129-133, 2019 Feb.
Article En | MEDLINE | ID: mdl-30259307

A 22-year-old HIV-negative man from Ghana was diagnosed with severe hemophagocytic lymphohistiocytosis (HLH) induced by multiorgan tuberculosis with peritoneal, hepatic, pericardial, myocardial, pleural, pulmonary, and bone manifestation. His body mass index was 12.9 m2/kg. Bioptic material of a peritoneal biopsy grew M. tuberculosis, sensitive to all first-line antituberculous drugs. HLH resolved with antituberculous therapy, without additional anti-inflammatory therapy being given. The initial CT scan of his brain was normal. After 5 months of antituberculous treatment, he developed a paralysis of the left arm. A cerebral MRT showed ring-enhanced lesions. Blood cultures and lumbar puncture revealed Cryptococcus neoformans var. grubi. The HIV test was repeatedly negative. Antituberculous treatment was continued for a total of 9 months, and additional treatment with antifungal therapy was established. He recovered fully after 14 months of antifungal treatment.


Cryptococcosis/diagnosis , Cryptococcus neoformans/isolation & purification , Immune Reconstitution Inflammatory Syndrome/diagnosis , Lymphohistiocytosis, Hemophagocytic/diagnosis , Tuberculosis/complications , Antifungal Agents/administration & dosage , Antitubercular Agents/administration & dosage , Brain/diagnostic imaging , Brain/microbiology , Brain/pathology , Cryptococcosis/diagnostic imaging , Cryptococcosis/drug therapy , Cryptococcosis/microbiology , Germany , Ghana/ethnology , HIV Seronegativity , Humans , Immune Reconstitution Inflammatory Syndrome/diagnostic imaging , Immune Reconstitution Inflammatory Syndrome/microbiology , Lymphohistiocytosis, Hemophagocytic/drug therapy , Lymphohistiocytosis, Hemophagocytic/microbiology , Male , Mycobacterium tuberculosis/isolation & purification , Tuberculosis/drug therapy , Young Adult
12.
Transpl Infect Dis ; 20(3): e12889, 2018 Jun.
Article En | MEDLINE | ID: mdl-29569815

Tuberculosis (TB) is an infrequent infection after hematopoietic cell transplant (HCT), with associated mortality up to 30%. The utility of universal screening for latent TB in HCT candidates is controversial due to the lack of sensitive screening tests. We describe a case of disseminated TB infection complicated by immune reconstitution inflammatory syndrome in an adult double unit umbilical cord blood transplant recipient who originated from the United Arab Emirates.


Fetal Blood/microbiology , Hematopoietic Stem Cell Transplantation/adverse effects , Immune Reconstitution Inflammatory Syndrome/microbiology , Transplant Recipients , Tuberculosis/diagnosis , Tuberculosis/transmission , Adult , Antitubercular Agents/therapeutic use , Diabetes Complications/microbiology , Diabetes Mellitus/microbiology , Humans , Immune Reconstitution Inflammatory Syndrome/diagnosis , Immune Reconstitution Inflammatory Syndrome/etiology , Leukemia, Myeloid, Acute/complications , Leukemia, Myeloid, Acute/microbiology , Male , Treatment Outcome , Tuberculosis/blood , Tuberculosis/etiology , Unrelated Donors
13.
Clin Infect Dis ; 67(3): 437-446, 2018 07 18.
Article En | MEDLINE | ID: mdl-29538651

Background: Immune reconstitution inflammatory syndrome (IRIS) is an aberrant inflammatory response in individuals with advanced human immunodeficiency virus (HIV) infection, after antiretroviral therapy (ART) initiation. The pathogenesis of Mycobacterium avium complex (MAC)-associated IRIS has not been fully elucidated. Methods: We investigated monocyte and CD4+ T-cell responses in vitro, tumor necrosis factor (TNF) expression in tissues, and plasma cytokines and inflammatory markers, in 13 HIV-infected patients with MAC-IRIS and 14 HIV-uninfected patients with pulmonary MAC infection. Results: Prior to ART, HIV-infected compared with HIV-uninfected patients, had reduced TNF+ monocytes (P = .013), although similar cytokine (interferon gamma [IFN-γ], TNF, interleukin 2 [IL-2], and interleukin 17 [IL-17])-expressing CD4+ T cells. During IRIS, monocyte cytokine production was restored. IFN-γ+ (P = .027), TNF+ (P = .004), and polyfunctional CD4+ T cells (P = 0.03) also increased. These effectors were T-betlow, and some expressed markers of degranulation and cytotoxic potential. Blockade of cytotoxic T-lymphocyte associated protein 4 and lymphocyte activation gene-3 further increased CD4+ T-cell cytokine production. Tissue immunofluorescence showed higher proportions of CD4+ and CD68+ (monocyte/macrophage) cells expressed TNF during IRIS compared with HIV-uninfected patients. Plasma IFN-γ (P = .048), C-reactive protein (P = .008), and myeloperoxidase (P < .001) levels also increased, whereas interleukin 10 decreased (P = .008) during IRIS. Conclusions: Advanced HIV infection was associated with impaired MAC responses. Restoration of monocyte responses and expansion of polyfunctional MAC-specific T-betlow CD4+ T cells with cytotoxic potential after ART initiation may overwhelm existing regulatory and inhibitory mechanisms, leading to MAC-IRIS.


CD4-Positive T-Lymphocytes/immunology , HIV Infections/complications , HIV Infections/immunology , Immune Reconstitution Inflammatory Syndrome/microbiology , T-Lymphocytes, Cytotoxic/immunology , Adult , Aged , Cohort Studies , Cytokines/immunology , Female , HIV Infections/microbiology , Humans , Immune Reconstitution Inflammatory Syndrome/immunology , Immune Reconstitution Inflammatory Syndrome/virology , Male , Middle Aged , Mycobacterium avium
14.
Enferm Infecc Microbiol Clin (Engl Ed) ; 36(10): 621-626, 2018 Dec.
Article En, Es | MEDLINE | ID: mdl-29187293

INTRODUCTION: The incidence of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients after an episode of Pneumocystis jirovecii pneumonia (PJP) seems to be lower than with other opportunistic infections. We conducted an observational study in order to determine the incidence, clinical characteristics and outcome of patients diagnosed with PJP-related IRIS. METHODS: We conducted an observational study of HIV patients diagnosed with PJP-related IRIS from January 2000 to November 2015. We analyzed epidemiological and clinical characteristics as well as laboratory findings. We also carried out a systematic review of published cases. RESULTS: Six cases of IRIS out of 123 (4.9%) HIV-infected patients with PJP who started ART were diagnosed. All six cases were men with a median age of 34 (IQR: 8) years. The six patients developed paradoxical IRIS. Subjects younger than 40 years old (p=0.084) and with an HIV-RNA viral load >100000 copies/ml (p=0.081) at diagnosis showed a tendency to develop IRIS. Thirty-seven published cases of PJP-related IRIS were identified. Although 51% of cases involved respiratory failure, no deaths were reported. CONCLUSIONS: PJP-related IRIS is rare condition compared to other opportunistic infections. It can lead to a severe respiratory failure in a significant proportion of cases, although no deaths have been reported.


HIV Infections/complications , Immune Reconstitution Inflammatory Syndrome/microbiology , Pneumocystis carinii , Pneumonia, Pneumocystis/complications , Adult , Female , Humans , Immune Reconstitution Inflammatory Syndrome/diagnosis , Immune Reconstitution Inflammatory Syndrome/epidemiology , Incidence , Male , Middle Aged , Retrospective Studies , Young Adult
15.
Gastroenterol Clin North Am ; 46(2): 327-343, 2017 06.
Article En | MEDLINE | ID: mdl-28506368

The improvement in antiretroviral therapy has significantly impacted the lives of people living with human immunodeficiency virus (HIV). In high-income countries, HIV deaths are predominated by liver disease consequent to viral hepatitis coinfection, alcohol, and nonalcoholic fatty liver disease. Published liver pathology findings have shifted from being predominated by opportunistic infections to the metabolic effects of HIV and antiretroviral therapy as well as drug-induced liver injuries. Differences remain between high-income and low-income countries, where opportunistic infections and immune reconstitution syndromes, dominate findings.


Anti-Retroviral Agents/therapeutic use , Chemical and Drug Induced Liver Injury/pathology , HIV Infections/drug therapy , HIV Infections/pathology , Liver/pathology , Reverse Transcriptase Inhibitors/therapeutic use , Anti-Retroviral Agents/adverse effects , Biopsy , Chemical and Drug Induced Liver Injury/diagnosis , Chemical and Drug Induced Liver Injury/etiology , Coinfection/complications , Coinfection/drug therapy , Coinfection/pathology , HIV Infections/complications , Hepatitis B, Chronic/complications , Hepatitis B, Chronic/pathology , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/pathology , Humans , Immune Reconstitution Inflammatory Syndrome/microbiology , Integrase Inhibitors/adverse effects , Protease Inhibitors/adverse effects , Reverse Transcriptase Inhibitors/adverse effects
16.
J Int Assoc Provid AIDS Care ; 16(4): 321-323, 2017.
Article En | MEDLINE | ID: mdl-28393665

Bacillary angiomatosis (BA) is a rare complication of human immune deficiency virus (HIV) infection in the post-antiretroviral therapy (ART) era, and few cases of BA-associated immune reconstitution inflammatory syndrome (IRIS) have been described. We report the case of a 50-year-old man who presented with mass lesions involving the skin, subcutaneous tissues, muscle, and bone. The diagnosis of Bartonella quintana BA was confirmed by serum polymerase chain reaction. The patient's treatment course was complicated by both IRIS and Jarisch-Herxheimer reaction. The case had a favorable outcome with supportive care and continuation of ART and doxycycline.


Bartonella quintana , HIV Infections/complications , Immune Reconstitution Inflammatory Syndrome/microbiology , Trench Fever/complications , Anti-Bacterial Agents/therapeutic use , Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , Humans , Male , Middle Aged , Trench Fever/drug therapy
17.
BMC Infect Dis ; 17(1): 305, 2017 04 24.
Article En | MEDLINE | ID: mdl-28438129

BACKGROUND: Due to its chronic subclinical course and large spectrum of manifestations, leprosy often represents a diagnostic challenge. Even with proper anti-mycobacteria treatment, leprosy follow up remains challenging: almost half of leprosy patients may develop reaction episodes. Leprosy is an infrequent complication of solid organ transplant recipients. This case report illustrates the challenges in diagnosing and managing leprosy and its reactional states in a transplant recipient. CASE PRESENTATION: A 53-year-old man presented 34 months after a successful renal transplantation a borderline-tuberculoid leprosy with signs of mild type 1 upgrading reaction (T1R). Cutaneous manifestations were atypical, and diagnosis was only made when granulomatous neuritis was found in a cutaneous biopsy. He was successfully treated with the WHO recommended multidrug therapy (MDT: rifampicin, dapsone and clofazimine). However he developed a severe T1R immediately after completion of the MDT but no signs of allograft rejection. T1R results from flare-ups of the host T-helper-1 cell-mediated immune response against Mycobacterium leprae antigens in patients with immunologically unstable, borderline forms of leprosy and has been considered an inflammatory syndrome in many aspects similar to the immune reconstitution inflammatory syndromes (IRS). The T1R was successfully treated by increasing the prednisone dose without modifying the other immunosuppressive drugs used for preventing allograft rejection. Immunological study revealed that the patient had a profound depletion of both in situ and circulating regulatory T-cells and lack of expansion of the Tregs upon M. leprae stimulation compared to T1R leprosy patients without iatrogenic immunosuppression. CONCLUSIONS: Our case report highlights that leprosy, especially in the transplant setting, requires a high degree of clinical suspicion and the contribution of histopathology. It also suggests that the development of upgrading inflammatory syndromes such as T1R can occur despite the sustained immunosuppressors regimen for preventing graft rejection. Our hypothesis is that the well-known deleterious effects of these immunosuppressors on pathogen-induced regulatory T-cells contributed to the immunedysregulation and development T1R.


Antigens, Bacterial/immunology , Immune Reconstitution Inflammatory Syndrome/diagnosis , Kidney Transplantation , Leprostatic Agents/administration & dosage , Leprosy/diagnosis , Mycobacterium leprae/immunology , Dapsone/administration & dosage , Drug Therapy, Combination , Graft Rejection/prevention & control , Humans , Immune Reconstitution Inflammatory Syndrome/drug therapy , Immune Reconstitution Inflammatory Syndrome/immunology , Immune Reconstitution Inflammatory Syndrome/microbiology , Immunosuppression Therapy , Leprosy/drug therapy , Leprosy/immunology , Leprosy/microbiology , Male , Middle Aged , Mycobacterium leprae/drug effects , Mycobacterium leprae/isolation & purification , Prednisone/administration & dosage , Rifampin/administration & dosage , Skin/immunology , Skin/microbiology , Skin/pathology , T-Lymphocytes, Regulatory/immunology , Treatment Outcome
19.
Rev. iberoam. micol ; 33(2): 118-121, abr.-jun. 2016. ilus
Article En | IBECS | ID: ibc-153955

Background. Fungal infections have been commonly diagnosed in individuals with advanced HIV disease. Cryptococcosis, pneumocystosis, and histoplasmosis are the most frequent systemic mycoses in people suffering from HIV/AIDS. Case report. We report a case of multiple fungal infections in an advanced AIDS-patient. A 33-year-old HIV-positive man from Brazil was hospitalized due to diarrhea, dyspnea, emaciation, hypoxemia, extensive oral thrush, and a CD4+ T lymphocyte count of 20 cells/mm3. Honeycombed-structures consistent with Pneumocystis jirovecii were observed by direct immunofluorescence in induced sputum. Cryptococcus neoformans was recovered from respiratory secretion and cerebrospinal fluid cultures. Histopathology of the bone marrow also revealed the presence of Histoplasma capsulatum. Molecular assays were performed in a sputum sample. Nested-PCR confirmed the presence of P. jirovecii and H. capsulatum; qPCR multiplex was positive for C. neoformans and H. capsulatum. With the treatment of antifungal drugs the patient progressed satisfactorily. Conclusions. The diagnosis of several systemic mycoses demonstrates the vulnerability of advanced AIDS-patients. Thus, the detection of AIDS cases in the early stages of infection is necessary for a prompt and adequate introduction of HAART therapy, and the use of prophylaxis to control opportunistic infections (AU)


Antecedentes. Las infecciones fúngicas se han diagnosticado comúnmente en individuos con enfermedad avanzada por VIH. La criptococosis, la neumocistosis y la histoplasmosis son las micosis sistémicas más frecuentes en personas con VIH/sida. Caso clínico. En este trabajo se describe un caso de múltiples infecciones fúngicas en un paciente con sida avanzado. Un hombre de 33 años, brasileño, con serología positiva para VIH, fue hospitalizado con pérdida de peso, diarrea, disnea, caquexia, hipoxemia, extensa candidiasis oral y recuento de linfocitos CD4+ de 20 cél./mm3. La inmunofluorescencia directa puso de manifiesto estructuras típicas compatibles con Pneumocystis jirovecii. En el cultivo de las muestras de secreción respiratoria y de líquido cefalorraquídeo creció Cryptococcus neoformans. En el análisis histopatológico de una muestra de médula ósea se observó Histoplasma capsulatum. Se llevaron a cabo ensayos de marcadores moleculares en una muestra de esputo. Se realizó un ensayo de PCR anidada que fue positivo para P. jirovecii y H. capsulatum, y una qPCR multiplex que fue positiva para C. neoformans e H. capsulatum. Con un tratamiento con antimicóticos el paciente evolucionó satisfactoriamente. Conclusiones. El diagnóstico de las micosis sistémicas demuestra la vulnerabilidad de los pacientes con sida avanzado. El diagnóstico de la infección por VIH en sus etapas iniciales es fundamental para la introducción precoz y adecuada de la terapia antirretroviral altamente activa y la profilaxis de las infecciones oportunistas (AU)


Humans , Male , Child , AIDS-Related Opportunistic Infections/complications , AIDS-Related Opportunistic Infections/diagnosis , AIDS-Related Opportunistic Infections/microbiology , Pneumonia, Pneumocystis/complications , Pneumonia, Pneumocystis/drug therapy , Histoplasmosis/complications , Histoplasmosis/drug therapy , Immune Reconstitution Inflammatory Syndrome/complications , Immune Reconstitution Inflammatory Syndrome/microbiology , Antifungal Agents/therapeutic use , AIDS-Related Opportunistic Infections/drug therapy , AIDS-Related Opportunistic Infections/physiopathology , Immune Reconstitution Inflammatory Syndrome/physiopathology , Immune Reconstitution Inflammatory Syndrome/drug therapy
20.
Oral Dis ; 22 Suppl 1: 46-52, 2016 Apr.
Article En | MEDLINE | ID: mdl-27109272

The symbiotic association of tuberculosis (TB) and HIV poses a challenge to human survival. HIV complicates every aspect of TB including presentation, diagnosis and treatment. HIV-TB patients encounter unique problems like drug-drug interactions, cumulative toxicity, immune reconstitution inflammatory syndrome (IRIS), lower plasma drug levels and emergence of drug resistance during treatment despite adherence. TB may also be overdiagnosed in HIV due to a number of diseases that closely resemble TB. Notable among them are non-tuberculous mycobacteria, Pneumocystis Jirovecii and Nocardia. Even though diagnostic procedures have improved over the years, patients in developing countries usually seek health care at later stage of the disease. Research data ascertains the duration of therapy for TB to be 6 months with rifampicin and isoniazid, reinforced with ethambutol and pyrazinamide in the first 2 months. The schedule of therapy is still debatable with daily regimens being preferred in the context of HIV. Many reasons exist for persistence of Mycobacterium Tuberculosis (M.TB) in sputum, or delayed-clearance of TB from sputum smears in HIV, apart from emergence of drug resistance and non-compliance. Acquired rifampicin resistance (ARR) is a unique phenomenon complicating HIV-associated TB when an intermittent regimen of antituberculosis therapy (ATT) is used without timely initiation of highly active antiretroviral therapy (HAART), especially in patients harbouring isoniazid-resistant strains Immune restoration is often incomplete ('swiss cheese' pattern) even with effective HAART if not started early. Immune reconstitution inflammatory syndrome (IRIS) is the paradoxical worsening of the patient's condition often with radiological deterioration, due to an enhanced immune response with HAART. IRIS occurs despite an effective virological suppression and a favourable response to ATT. The incidence of IRIS in HIV has reached up to 54%, requiring utilization of experts and tertiary care which forms an obstacle to the decentralization of patients in the ART programme. Research in HIV-TB immunology and management needs further exploration in order to understand the diseases and offer appropriate treatment. The following paragraphs provide scientific evidences generated through research that could potentially guide management.


Anti-HIV Agents/therapeutic use , Antitubercular Agents/therapeutic use , Coinfection/drug therapy , HIV Infections/drug therapy , Immune Reconstitution Inflammatory Syndrome/microbiology , Tuberculosis, Pulmonary/drug therapy , Antiretroviral Therapy, Highly Active , Coinfection/diagnosis , Humans , Immune Reconstitution Inflammatory Syndrome/diagnosis , Immune Reconstitution Inflammatory Syndrome/drug therapy , Immune Reconstitution Inflammatory Syndrome/prevention & control , Tuberculosis, Pulmonary/diagnosis
...